<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00749788</url>
  </required_header>
  <id_info>
    <org_study_id>AT302-U-06-003</org_study_id>
    <nct_id>NCT00749788</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of JTT-302 in Subjects With Low HDL-C Levels</brief_title>
  <official_title>A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group Study Evaluating the Efficacy and Safety of JTT-302 Administered Daily for Four Weeks in Subjects With Low HDL-C Levels</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Akros Pharma Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Akros Pharma Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effect of JTT-302 on the increase of High
      Density Lipoprotein-Cholesterol (HDL-C) levels when administered daily for four weeks in
      subjects with low HDL-C levels.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change from baseline in HDL-C at Week 4</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent change and change from baseline at week 4 in lipid parameters</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the safety profile of JTT-302 when administered for 4 weeks</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>JTT-302, 200 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>JTT-302, 400 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JTT-302</intervention_name>
    <description>JTT-302, 100 mg tablets, 200 mg dose, oral, 30 minutes after the start of the morning meal</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JTT-302</intervention_name>
    <description>JTT-302, 100 mg tablets, 400 mg dose, oral, 30 minutes after the start of the morning meal</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo tablets, oral, 30 minutes after the start of the morning meal</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with a Body Mass Index (BMI)≤ 35 kg/m2

          -  Subjects with the following lipid parameters at Visit 1 (screening visit) and Visit 3
             (diet stabilization period):

          -  HDL-C ≤ 40 mg/dL (Men) and ≤ 50 mg/dL (Women)

          -  TG ≤ 500 mg/dL

          -  LDL-C ≤ 190 mg/dL

          -  Subjects who are generally healthy as determined by pre-study medical history,
             physical examination, vital signs and 12-lead ECG

        Exclusion Criteria:

          -  Females who are pregnant or breast-feeding

          -  AST, ALT or total bilirubin ≥ 2.0 x ULN at Visit 1 (screening visit) or Visit 3 (diet
             stabilization period)

          -  Serum thyroid stimulating hormone (TSH) and levothyroxine (T4) outside of the central
             laboratory reference range at the screening visit

          -  Medical history of diabetes mellitus or two fasting serum glucose measurements &gt; 126
             mg/dL at the screening visit

          -  Subjects with hypertension, or two blood pressure measurements ≥ 140 mm Hg systolic or
             ≥ 90 mm Hg diastolic at the screening visit

          -  History of drug or alcohol abuse within 12 months of the screening visit

          -  Use of medications defined in the protocol within six-weeks prior to the screening
             visit and throughout the study

          -  Use of Cytochrome P450 3A4 inducers or inhibitors, as defined in the protocol within
             four weeks of the screening visit and throughout the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 5, 2008</study_first_submitted>
  <study_first_submitted_qc>September 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2008</study_first_posted>
  <disposition_first_submitted>January 31, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>January 31, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 4, 2013</disposition_first_posted>
  <last_update_submitted>January 31, 2013</last_update_submitted>
  <last_update_submitted_qc>January 31, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

